Bryan Johnson's Peptide Protocol: What He Actually Uses (And What He Doesn't)

Why This Guide Exists

Bryan Johnson's Blueprint protocol is one of the most searched longevity stacks on the internet. He is a polarizing public figure with a documented protocol and a consumer product business built around it — and his habit of measuring everything and publishing the results makes him uniquely searchable. When someone decides to explore research peptides or longevity supplements, his name comes up immediately.

The problem is that a large share of what appears under his name online is simply wrong. Articles with titles like "Bryan Johnson's complete supplement stack" or "What peptides Bryan Johnson uses" routinely list compounds he has never mentioned. Some of these articles are speculative extrapolations — "if he were optimizing for X, he'd probably use Y" — that have been stripped of their hedging language over successive reposts. Others appear to be vendor marketing, attaching a high-profile name to a product to drive traffic and sales.

This matters because people are making decisions — sometimes significant ones about substances with real physiological effects — based on what they believe Bryan Johnson uses. The correct use of his protocol as a reference point requires knowing what he actually does, not what the internet has decided he must do.

BetterNewLives.com exists to be the honest source. This guide uses only primary sources and says directly when a claim is confirmed, when it is past experimentation, and when it is simply not supported.

Who Bryan Johnson Is — Brief, Neutral

Bryan Johnson is a technology entrepreneur who sold Braintree/Venmo to PayPal in 2013 for $800 million and subsequently founded Kernel, a company developing brain-computer interface technology. Since approximately 2021, he has become publicly known primarily for Blueprint — a personal longevity protocol he has designed and documented in extensive detail, run on himself, and now commercialized as a consumer product company.

The protocol involves an approximately 2,000-calorie-per-day vegan diet (with very specific foods and timing), a regimented daily exercise routine (reportedly over an hour per day), highly optimized sleep, and a substantial stack of prescription medications and supplements measured and timed precisely. He has a team of physicians and researchers supporting his protocol design and interpretation.

Johnson's epigenetic age test results have shown meaningful improvements from his biological baseline, and he has shared these publicly. He has been covered extensively in mainstream media and has attracted both enthusiastic followers and serious criticism from academic longevity researchers.

The following compounds are confirmed through primary sources — his published protocol, Blueprint product disclosures, or his own confirmed statements. Each entry includes the source of confirmation and a clear description of how he actually uses it. Route of administration matters significantly and is frequently misrepresented.

GHK-Cu: Topical, Not Injectable

This is the most important specific correction in this guide. GHK-Cu is genuinely in Bryan Johnson's protocol — but it is in his facial serum and scalp serum, applied topically, as a cosmetic ingredient. It is not part of an injectable research peptide regimen. When biohacking forums discuss "Bryan Johnson's GHK-Cu protocol," they are often implicitly framing it as injectable use. That is not what his protocol shows.

The distinction matters because topical GHK-Cu and injectable GHK-Cu have very different evidence bases, risk profiles, and implications. For a detailed breakdown of those differences, see our GHK-Cu guide. Johnson's use of it in a cosmetic formulation is consistent with the strongest evidence base for GHK-Cu, which is in skin and hair contexts. His use does not validate or imply injectable use.

TB-4 Fragment: Same Point Applies

Thymosin Beta-4 fragment — sometimes discussed in research peptide communities as a component of TB-500 products — appears in Blueprint scalp formulations, again topically. TB-500 in research peptide contexts is typically used by injection for its systemic effects on muscle repair and recovery. Johnson's use of the TB-4 fragment in a scalp topical for hair support is a categorically different application. Internet claims that "Bryan Johnson uses TB-500" need to be read against this context: he uses a TB-4 fragment topically for scalp health, not injectable TB-500 for systemic recovery.

BPC-157: Experimented With, Not Current

In April 2025, Johnson posted on X about his experience with BPC-157 and Cerebrolysin. He described BPC-157 as "effective when used precisely" — language suggesting careful, experimental use. He did not describe it as part of his ongoing, active protocol. BPC-157 does not appear in his published protocol at protocol.bryanjohnson.com as a current compound. The confirmation here is that he experimented with it and found it effective in some context — not that it is part of what he is doing now.

This nuance is lost in most third-party coverage, which either omits BPC-157 entirely or lists it as a current stack item. Neither extreme is accurate.

Tirzepatide: A Three-Week Experiment He Stopped

Johnson has publicly described a brief tirzepatide microdosing experiment, lasting approximately three weeks. He stopped it after observing elevated resting heart rate and sleep degradation — consistent with known side effect profiles of GLP-1/GIP agonists at higher doses, though his microdosing approach is separate from standard therapeutic dosing. This is documented in his public disclosures and is among the more transparent examples of him sharing what did not work. For a full discussion, see our guide on his tirzepatide experiment.

The following compounds are routinely listed in third-party "Bryan Johnson stack" articles, Reddit posts, vendor marketing materials, and biohacking forums. None are supported by a primary source — his published protocol, his confirmed social posts, or Blueprint product disclosures — as of May 2026. Each entry describes why it circulates despite having no evidential basis.

The Fan-Fiction Problem Explained

Understanding why the internet has created a fictional Bryan Johnson supplement stack is useful for anyone trying to do research in the longevity and biohacking space, because the same dynamics generate misinformation about other public figures and protocols.

How False Claims Propagate

The typical lifecycle of a false Bryan Johnson peptide claim follows a predictable pattern. First, someone in a biohacking community asks: "Do you think Bryan Johnson uses X?" — a speculative question with explicit hedging. Someone replies with a plausible explanation of why X would fit his goals. That exchange gets summarized: "People think Bryan Johnson uses X." That summary gets aggregated into a listicle: "Bryan Johnson's top 10 peptides." The listicle gets scraped by other content producers, stripped of any remaining hedging, and republished as fact. Several iterations later, "Bryan Johnson uses X" is stated as a given in forum discussions, vendor copy, and SEO-optimized articles.

The "Plausible Stack" Extrapolation Problem

A specific variant of the misinformation problem is expert extrapolation. Researchers and podcast hosts in the longevity space sometimes discuss what Bryan Johnson's protocol "should" include based on emerging science — essentially constructing a hypothetical optimal protocol and attributing it to him. This is a legitimate intellectual exercise when properly framed, but when stripped of context it becomes false attribution. The question "if you were designing Bryan Johnson's ideal protocol, would you add MOTS-c?" is a different question from "does Bryan Johnson use MOTS-c?" These questions get conflated.

What This Means for Your Research

If you encounter a claim that Bryan Johnson uses a specific peptide and want to verify it, the standard is simple: can you find it in his published protocol at protocol.bryanjohnson.com, in a Blueprint product ingredient disclosure, or in a confirmed statement by Johnson on X or in a documented interview? If the answer is no, treat the claim as unverified regardless of how many secondary sources repeat it.

The volume of repetition of a claim is not evidence that the claim is true. In the internet biohacking content ecosystem, wrong claims can propagate faster than corrections. Primary sources are the only reliable check.

His Actual Protocol Foundation — Context That Matters

To accurately evaluate what the peptide-relevant compounds in Johnson's protocol actually contribute — or might contribute — it is essential to understand the structure of the protocol as a whole. The peptide and topical components are a small slice of a much larger intervention.

The Primary Foundations

Based on his published protocol, the documented foundations of Blueprint are:

• Sleep optimization: Johnson treats sleep as the single highest-priority intervention. This includes precise sleep and wake timing, measured and optimized continuously, with multiple tracking devices. He has described sleep quality as more foundational than any supplement intervention.
• Diet: A vegan diet, approximately 2,000–2,250 calories per day, heavily structured around specific foods (extra virgin olive oil, almonds, broccoli sprouts, berries, specific legumes, dark chocolate). Calorie timing is also structured, with no eating after a certain daily cutoff.
• Exercise: An intensive daily protocol of over an hour including high-intensity cardiovascular training, strength training, and flexibility work.
• Prescription medications: Including metformin, an SGLT-2 inhibitor (dapagliflozin), a low-dose statin, and several other prescription agents — this is the most intervention-dense part of his protocol relative to typical longevity discussions.
• Foundational supplements: NMN (1g/day), creatine (2.5g/day), EPA/DHA, CoQ10, lithium (low-dose), vitamin D3+K2, zinc, magnesium, and a range of others — most published in his protocol with specific doses and timing.

The Peptide Component in Context

Against that background, the confirmed peptide-relevant items are: topical cosmetic formulations (GHK-Cu and TB-4 fragment in skincare/hair products), oral collagen peptides (12.5g/day, a mainstream supplement with a reasonable evidence base), and two past experiments (BPC-157 and tirzepatide) that are not current. This is the complete picture from primary sources.

The internet discussion of Bryan Johnson and peptides dramatically overweights the peptide component relative to his actual documented protocol emphasis. His foundational interventions are sleep, diet, exercise, and prescription medications. The peptide-adjacent items are a small, largely topical and experimental component.

Bryan Johnson's protocol has attracted serious scientific criticism alongside its enthusiastic popular reception, and engaging with that criticism honestly is part of BNL's commitment to accuracy.

The Criticism From Longevity Researchers

Leading longevity researchers have raised methodological objections to how Johnson presents his results. Dr. Matt Kaeberlein at the University of Washington — one of the more prominent academic researchers in the longevity field — has publicly noted that Johnson's protocol is an uncontrolled n=1 experiment in which the many simultaneous interventions make it impossible to attribute observed changes to any specific cause. This is not a fringe criticism; it reflects basic principles of experimental design.

The specific concern is causation versus correlation. Johnson's epigenetic age measurements show improvement. But without a control arm, without systematic variation of individual interventions, and with hundreds of simultaneous changes to diet, exercise, medications, supplements, sleep, and other variables, there is no scientific method available to determine which intervention, or which combination of interventions, is responsible for the observed changes. Johnson's favorable biomarker trends are an interesting data point. They are not evidence that any specific intervention works.

The Measurement Validity Question

Epigenetic age clocks — the primary tool Johnson uses to track biological aging — are themselves an active area of methodological debate. Different clocks (Horvath, Levine, DunedinPACE, etc.) measure different aspects of DNA methylation patterns and do not always agree. The predictive validity of improvements on these clocks for actual health outcomes and lifespan has not been established in long-term prospective studies. Clock improvement may reflect genuine biological changes, or it may reflect artifacts of the specific interventions in ways that do not translate to downstream health outcomes.

This does not mean epigenetic age testing is worthless. It means the field is young, the tools are promising but not validated as endpoints, and interpreting Johnson's clock results as confirmed longevity benefit is an inferential step that the evidence does not currently support.

BNL's Position

Johnson's protocol is neither the miraculous breakthrough his most enthusiastic followers believe it to be nor the vanity project his most dismissive critics describe. It is a serious, expensive, well-documented n=1 experiment by a credible individual who is genuinely committed to the work. Its limitations are methodological, not motivational. BNL presents his protocol accurately — including both what is genuinely interesting about it and where the scientific evidence falls short.

This is the most important pivot in this guide: from "what does Bryan Johnson use" to "what does the evidence actually show." The compounds in BNL's coverage have research bases that are independent of Bryan Johnson's use or non-use of them. Those evidence bases are the correct reference point for anyone making decisions about these compounds.

GHK-Cu: The Connection to His Protocol Is Real, But Narrow

Johnson genuinely uses GHK-Cu. But he uses it topically in cosmetic formulations, which is the context with the best evidence base. The large independent literature on GHK-Cu — wound healing, collagen synthesis, skin repair — is relevant to evaluating the compound. What Johnson's use does not validate is systemic injectable GHK-Cu, which is what much of the biohacking community discussion focuses on. For a full treatment of what the GHK-Cu evidence actually shows, see our GHK-Cu guide.

BPC-157: Evidence Exists, Johnson's Use Is Past Tense

BPC-157 has one of the more interesting preclinical evidence bases in the research peptide space — robust animal studies in GI protection, soft tissue repair, and neurotrophic effects. Johnson's acknowledgment that he found it "effective when used precisely" is consistent with community experience but does not substitute for clinical trial data. The evidence for BPC-157 should be evaluated based on its own literature, not on Johnson's past experimentation. For relevant BNL content on BPC-157, see our peptide quality risks guide.

Epithalon: Evidence Worth Knowing Despite No Johnson Connection

Epithalon is an interesting case because it is among the most falsely attributed compounds to Johnson and simultaneously one of the peptides with the most interesting — if preliminary — independent research base. The Russian literature on Epithalon includes small human trials suggesting effects on telomere length and immune function in elderly populations. These studies have methodological limitations and have not been replicated in large Western RCTs. But they are human studies, which is more than many research peptides can claim. The evidence for Epithalon deserves evaluation on its own merits, independent of Johnson's non-use of it.

The Correct Framework

The right question is never "does Bryan Johnson use X." His protocol is one n=1 data point from a person whose characteristics, resources, and simultaneous interventions are unlikely to match your situation. The right questions are: What does the peer-reviewed evidence show about X for my specific goals? What is the quality of that evidence? What is the risk profile? What is the status of the supply chain for a research-grade version of this compound? Those questions have answers that BNL covers in the compound-specific guides linked below.

Frequently Asked Questions